Stage-specific action of matrix metalloproteinases influences progressive hereditary kidney disease

Michael Zeisberg, Mona Khurana, Velidi H. Rao, Dominic E Cosgrove, Jean Philippe Rougier, Michelle C. Werner, Charles F. Shield, Zena Werb, Raghu Kalluri

Research output: Contribution to journalArticle

108 Citations (Scopus)

Abstract

Background: Glomerular basement membrane (GBM), a key component of the blood-filtration apparatus in the in the kidney, is formed through assembly of type IV collagen with laminins, nidogen, and sulfated proteoglycans. Mutations or deletions involving α3(IV), α4(IV), or α5(IV) chains of type IV collagen in the GBM have been identified as the cause for Alport syndrome in humans, a progressive hereditary kidney disease associated with deafness. The pathological mechanisms by which such mutations lead to eventual kidney failure are not completely understood. Methods and Findings: We showed that increased susceptibility of defective human Alport GBM to proteolytic degradation is mediated by three different matrix metalloproteinases (MMPs) - MMP-2, MMP-3, and MMP-9 - which influence the progression of renal dysfunction in α3(IV)-/- mice, a model for human Alport syndrome. Genetic ablation of either MMP-2 or MMP-9, or both MMP-2 and MMP-9, led to compensatory up-regulation of other MMPs in the kidney glomerulus. Pharmacological ablation of enzymatic activity associated with multiple GBM-degrading MMPs, before the onset of proteinuria or GBM structural defects in the α3(IV)-/- mice, led to significant attenuation in disease progression associated with delayed proteinuria and marked extension in survival. In contrast, inhibition of MMPs after induction of proteinuria led to acceleration of disease associated with extensive interstitial fibrosis and early death of α3(IV)-/- mice. Conclusions: These results suggest that preserving GBM/extracellular matrix integrity before the onset of proteinuria leads to significant disease protection, but if this window of opportunity is lost, MMP-inhibition at the later stages of Alport disease leads to accelerated glomerular and interstitial fibrosis. Our findings identify a crucial dual role for MMPs in the progression of Alport disease in α3(IV)-/- mice, with an early pathogenic function and a later protective action. Hence, we propose possible use of MMP-inhibitors as disease-preventive drugs for patients with Alport syndrome with identified genetic defects, before the onset of proteinuria.

Original languageEnglish (US)
Pages (from-to)535-546
Number of pages12
JournalPLoS Medicine
Volume3
Issue number4
DOIs
StatePublished - Apr 1 2006

Fingerprint

Glomerular Basement Membrane
Inborn Genetic Diseases
Kidney Diseases
Matrix Metalloproteinases
Proteinuria
Hereditary Nephritis
Matrix Metalloproteinase 2
Matrix Metalloproteinase 9
Collagen Type III
Disease Progression
Fibrosis
Kidney Glomerulus
Kidney
Matrix Metalloproteinase 3
Matrix Metalloproteinase Inhibitors
Sequence Deletion
Deafness
Laminin
Proteoglycans
Renal Insufficiency

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Stage-specific action of matrix metalloproteinases influences progressive hereditary kidney disease. / Zeisberg, Michael; Khurana, Mona; Rao, Velidi H.; Cosgrove, Dominic E; Rougier, Jean Philippe; Werner, Michelle C.; Shield, Charles F.; Werb, Zena; Kalluri, Raghu.

In: PLoS Medicine, Vol. 3, No. 4, 01.04.2006, p. 535-546.

Research output: Contribution to journalArticle

Zeisberg, M, Khurana, M, Rao, VH, Cosgrove, DE, Rougier, JP, Werner, MC, Shield, CF, Werb, Z & Kalluri, R 2006, 'Stage-specific action of matrix metalloproteinases influences progressive hereditary kidney disease', PLoS Medicine, vol. 3, no. 4, pp. 535-546. https://doi.org/10.1371/journal.pmed.0030100
Zeisberg, Michael ; Khurana, Mona ; Rao, Velidi H. ; Cosgrove, Dominic E ; Rougier, Jean Philippe ; Werner, Michelle C. ; Shield, Charles F. ; Werb, Zena ; Kalluri, Raghu. / Stage-specific action of matrix metalloproteinases influences progressive hereditary kidney disease. In: PLoS Medicine. 2006 ; Vol. 3, No. 4. pp. 535-546.
@article{f2811f1aa3d04014902cbf3a9db43817,
title = "Stage-specific action of matrix metalloproteinases influences progressive hereditary kidney disease",
abstract = "Background: Glomerular basement membrane (GBM), a key component of the blood-filtration apparatus in the in the kidney, is formed through assembly of type IV collagen with laminins, nidogen, and sulfated proteoglycans. Mutations or deletions involving α3(IV), α4(IV), or α5(IV) chains of type IV collagen in the GBM have been identified as the cause for Alport syndrome in humans, a progressive hereditary kidney disease associated with deafness. The pathological mechanisms by which such mutations lead to eventual kidney failure are not completely understood. Methods and Findings: We showed that increased susceptibility of defective human Alport GBM to proteolytic degradation is mediated by three different matrix metalloproteinases (MMPs) - MMP-2, MMP-3, and MMP-9 - which influence the progression of renal dysfunction in α3(IV)-/- mice, a model for human Alport syndrome. Genetic ablation of either MMP-2 or MMP-9, or both MMP-2 and MMP-9, led to compensatory up-regulation of other MMPs in the kidney glomerulus. Pharmacological ablation of enzymatic activity associated with multiple GBM-degrading MMPs, before the onset of proteinuria or GBM structural defects in the α3(IV)-/- mice, led to significant attenuation in disease progression associated with delayed proteinuria and marked extension in survival. In contrast, inhibition of MMPs after induction of proteinuria led to acceleration of disease associated with extensive interstitial fibrosis and early death of α3(IV)-/- mice. Conclusions: These results suggest that preserving GBM/extracellular matrix integrity before the onset of proteinuria leads to significant disease protection, but if this window of opportunity is lost, MMP-inhibition at the later stages of Alport disease leads to accelerated glomerular and interstitial fibrosis. Our findings identify a crucial dual role for MMPs in the progression of Alport disease in α3(IV)-/- mice, with an early pathogenic function and a later protective action. Hence, we propose possible use of MMP-inhibitors as disease-preventive drugs for patients with Alport syndrome with identified genetic defects, before the onset of proteinuria.",
author = "Michael Zeisberg and Mona Khurana and Rao, {Velidi H.} and Cosgrove, {Dominic E} and Rougier, {Jean Philippe} and Werner, {Michelle C.} and Shield, {Charles F.} and Zena Werb and Raghu Kalluri",
year = "2006",
month = "4",
day = "1",
doi = "10.1371/journal.pmed.0030100",
language = "English (US)",
volume = "3",
pages = "535--546",
journal = "PLoS Medicine",
issn = "1549-1277",
number = "4",

}

TY - JOUR

T1 - Stage-specific action of matrix metalloproteinases influences progressive hereditary kidney disease

AU - Zeisberg, Michael

AU - Khurana, Mona

AU - Rao, Velidi H.

AU - Cosgrove, Dominic E

AU - Rougier, Jean Philippe

AU - Werner, Michelle C.

AU - Shield, Charles F.

AU - Werb, Zena

AU - Kalluri, Raghu

PY - 2006/4/1

Y1 - 2006/4/1

N2 - Background: Glomerular basement membrane (GBM), a key component of the blood-filtration apparatus in the in the kidney, is formed through assembly of type IV collagen with laminins, nidogen, and sulfated proteoglycans. Mutations or deletions involving α3(IV), α4(IV), or α5(IV) chains of type IV collagen in the GBM have been identified as the cause for Alport syndrome in humans, a progressive hereditary kidney disease associated with deafness. The pathological mechanisms by which such mutations lead to eventual kidney failure are not completely understood. Methods and Findings: We showed that increased susceptibility of defective human Alport GBM to proteolytic degradation is mediated by three different matrix metalloproteinases (MMPs) - MMP-2, MMP-3, and MMP-9 - which influence the progression of renal dysfunction in α3(IV)-/- mice, a model for human Alport syndrome. Genetic ablation of either MMP-2 or MMP-9, or both MMP-2 and MMP-9, led to compensatory up-regulation of other MMPs in the kidney glomerulus. Pharmacological ablation of enzymatic activity associated with multiple GBM-degrading MMPs, before the onset of proteinuria or GBM structural defects in the α3(IV)-/- mice, led to significant attenuation in disease progression associated with delayed proteinuria and marked extension in survival. In contrast, inhibition of MMPs after induction of proteinuria led to acceleration of disease associated with extensive interstitial fibrosis and early death of α3(IV)-/- mice. Conclusions: These results suggest that preserving GBM/extracellular matrix integrity before the onset of proteinuria leads to significant disease protection, but if this window of opportunity is lost, MMP-inhibition at the later stages of Alport disease leads to accelerated glomerular and interstitial fibrosis. Our findings identify a crucial dual role for MMPs in the progression of Alport disease in α3(IV)-/- mice, with an early pathogenic function and a later protective action. Hence, we propose possible use of MMP-inhibitors as disease-preventive drugs for patients with Alport syndrome with identified genetic defects, before the onset of proteinuria.

AB - Background: Glomerular basement membrane (GBM), a key component of the blood-filtration apparatus in the in the kidney, is formed through assembly of type IV collagen with laminins, nidogen, and sulfated proteoglycans. Mutations or deletions involving α3(IV), α4(IV), or α5(IV) chains of type IV collagen in the GBM have been identified as the cause for Alport syndrome in humans, a progressive hereditary kidney disease associated with deafness. The pathological mechanisms by which such mutations lead to eventual kidney failure are not completely understood. Methods and Findings: We showed that increased susceptibility of defective human Alport GBM to proteolytic degradation is mediated by three different matrix metalloproteinases (MMPs) - MMP-2, MMP-3, and MMP-9 - which influence the progression of renal dysfunction in α3(IV)-/- mice, a model for human Alport syndrome. Genetic ablation of either MMP-2 or MMP-9, or both MMP-2 and MMP-9, led to compensatory up-regulation of other MMPs in the kidney glomerulus. Pharmacological ablation of enzymatic activity associated with multiple GBM-degrading MMPs, before the onset of proteinuria or GBM structural defects in the α3(IV)-/- mice, led to significant attenuation in disease progression associated with delayed proteinuria and marked extension in survival. In contrast, inhibition of MMPs after induction of proteinuria led to acceleration of disease associated with extensive interstitial fibrosis and early death of α3(IV)-/- mice. Conclusions: These results suggest that preserving GBM/extracellular matrix integrity before the onset of proteinuria leads to significant disease protection, but if this window of opportunity is lost, MMP-inhibition at the later stages of Alport disease leads to accelerated glomerular and interstitial fibrosis. Our findings identify a crucial dual role for MMPs in the progression of Alport disease in α3(IV)-/- mice, with an early pathogenic function and a later protective action. Hence, we propose possible use of MMP-inhibitors as disease-preventive drugs for patients with Alport syndrome with identified genetic defects, before the onset of proteinuria.

UR - http://www.scopus.com/inward/record.url?scp=33646266237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646266237&partnerID=8YFLogxK

U2 - 10.1371/journal.pmed.0030100

DO - 10.1371/journal.pmed.0030100

M3 - Article

C2 - 16509766

AN - SCOPUS:33646266237

VL - 3

SP - 535

EP - 546

JO - PLoS Medicine

JF - PLoS Medicine

SN - 1549-1277

IS - 4

ER -